Press Releases Sanofi Xetra

Equities

SNW

FR0000120578

Market Closed - Xetra Other stock markets 16:35:37 17/05/2024 BST			5-day change	1st Jan Change
88.86 ^EUR	-1.15%		-5.70%	-0.98%

05-15	Transcript : Sanofi Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM
05-14	Global markets live: Apple, Sony, Vodafone, Booking, Walmart...

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enabling The "Full Scope" Of Claims In View Of The Supreme Court's Decision In Amgen	05-13	AQ
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines	05-13	AQ
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights	05-13	AQ
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty	05-13	GL
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines	05-10	GL
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations	05-02	GL
Press Release: Annual General Meeting of April 30, 2024	04-30	GL
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024	04-30	AQ
Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases	04-26	PU
Sanofi Q1 robust 7% sales growth driven by launches, underpins full-year guidance	04-26	AQ
Sanofi: Q1 Earnings Snapshot	04-25	AQ
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance	04-25	GL
AusBiotech announces incoming CEO	04-24	AQ
Sanofi - Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	04-24	AQ
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	04-23	GL
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	04-23	AQ
The 2023 Pharmaceutical Patent Review	04-17	AQ
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis	04-17	GL
INNATE PHARMA ANNOUNCES ADVANCEMENT OF SANOFI-DEVELOPED NK CELL ENGAGER SAR443579/IPH6101 PROGRESSING TO PHASE 2 FOR BLOOD CANCER PATIENTS	04-16	AQ
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents	04-08	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 12:58 pm

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 08:56 pm